Rhythm Pharmaceuticals Net Worth
Rhythm Pharmaceuticals Net Worth Breakdown | RYTM |
Rhythm Pharmaceuticals Net Worth Analysis
Rhythm Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Rhythm Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Rhythm Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Rhythm Pharmaceuticals' net worth analysis. One common approach is to calculate Rhythm Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Rhythm Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Rhythm Pharmaceuticals' net worth. This approach calculates the present value of Rhythm Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Rhythm Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Rhythm Pharmaceuticals' net worth. This involves comparing Rhythm Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Rhythm Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Rhythm Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rhythm Pharmaceuticals' net worth research are outlined below:
| Rhythm Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 77.43 M. Net Loss for the year was (184.68 M) with profit before overhead, payroll, taxes, and interest of 21.5 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (136.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone - MSN |
Rhythm Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rhythm Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rhythm Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Rhythm Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rhythm Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rhythm Pharmaceuticals backward and forwards among themselves. Rhythm Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rhythm Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rock Springs Capital Management Lp | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-06-30 | 1.3 M | Commodore Capital Lp | 2024-06-30 | 1.2 M | Driehaus Capital Management Llc | 2024-06-30 | 1.2 M | Alkeon Capital Management, Llc | 2024-09-30 | 1.2 M | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 951.3 K | Pictet Asset Manangement Sa | 2024-06-30 | 801.8 K | Orbimed Advisors, Llc | 2024-06-30 | 704.8 K | Primecap Management Company | 2024-09-30 | 7.2 M | Blackrock Inc | 2024-06-30 | 6.7 M |
Follow Rhythm Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.63 B.Market Cap |
|
Project Rhythm Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.57) | (0.60) | |
| Return On Capital Employed | (0.66) | (0.63) | |
| Return On Assets | (0.56) | (0.58) | |
| Return On Equity | (1.09) | (1.03) |
When accessing Rhythm Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Rhythm Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rhythm Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Rhythm Pharmaceuticals' management efficiency
Rhythm Pharmaceuticals has return on total asset (ROA) of (0.4624) % which means that it has lost $0.4624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.479) %, meaning that it created substantial loss on money invested by shareholders. Rhythm Pharmaceuticals' management efficiency ratios could be used to measure how well Rhythm Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.6. In addition to that, Return On Capital Employed is likely to grow to -0.63. At this time, Rhythm Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Non Currrent Assets Other is likely to grow to about 16.1 M, while Other Current Assets are likely to drop about 5.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.94 | 2.97 | |
| Tangible Book Value Per Share | 2.82 | 2.94 | |
| Enterprise Value Over EBITDA | (15.39) | (16.16) | |
| Price Book Value Ratio | 15.62 | 16.40 | |
| Enterprise Value Multiple | (15.39) | (16.16) | |
| Price Fair Value | 15.62 | 16.40 | |
| Enterprise Value | 2.6 B | 2.7 B |
Understanding the operational decisions made by Rhythm Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 29.803 | Revenue 112.5 M | Quarterly Revenue Growth 0.478 | Revenue Per Share 1.863 | Return On Equity (1.48) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rhythm Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rhythm Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rhythm Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rhythm Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 13th of November 2024 Other Reports | ViewVerify | |
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Rhythm Pharmaceuticals Earnings per Share Projection vs Actual
Rhythm Pharmaceuticals Corporate Management
| Jennifer Lee | Executive America | Profile | |
| Yann Mazabraud | Executive International | Profile | |
| Christopher German | Principal Controller | Profile | |
| Sarah Ryan | Vice Marketing | Profile | |
| Jim Flaherty | Senior Counsel | Profile | |
| David Connolly | Head Communications | Profile | |
| Joseph Shulman | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.